Halozyme Therapeutics, Inc. - Common Stock (HALO)
57.63
+0.86 (1.51%)
Halozyme Therapeutics is a biotechnology company that focuses on the development and commercialization of novel therapeutics for the treatment of various diseases, particularly in oncology and chronic diseases
The company specializes in its proprietary proprietary enzyme technology, which enhances the delivery and effectiveness of therapeutics, including biologics and monoclonal antibodies. Halozyme collaborates with other pharmaceutical companies to improve their drug formulations and patient delivery systems, ultimately aiming to provide innovative solutions that enhance treatment outcomes for patients.
Frequently Asked Questions
Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 57.63
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 4:00 pm EST on February 5th, 2025
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 8.20B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 142.33M shares outstanding.